Molecular and cytometric analysis of renal cell carcinoma cells. Concept, techniques and prospects;Analyse moléculaire et cytométrique des cellules d'adénocarcinome rénal. Concepts, techniques et perspectives

Progres en Urologie

Volumn 13, Issue 1, 2003, Pages 1-13

  Guorong, Ll ^a   Lambert, Claude ^a   Gentil Perret, Anne ^a   Genin, Christian ^a   Tostain, Jacques ^a  

^a HÔPITAL NORD   (France)

Author keywords

Adenocarcinoma; Biological markers; Kidney

Indexed keywords

ANTIGEN; CADHERIN; CADHERIN 6 ANTIGEN; CALPAIN; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE 12; CARBONATE DEHYDRATASE 9; CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOKERATIN 7; DNA; FAS ANTIGEN; GALECTIN; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; MARKER; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN BCL 2; PROTEIN P53; PROTEINASE; RAS PROTEIN; SIALYL LEWIS X ANTIGEN; TETRACYCLINE; TIAM 1 PROTEIN; TRANSCRIPTION FACTOR PAX2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIMENTIN;

ASPIRATION CYTOLOGY; BIOPSY; CANCER DIAGNOSIS; CANCER INVASION; CARCINOMA CELL; CHROMOSOME ABERRATION; CHROMOSOME MUTATION; CHROMOSOME TRANSLOCATION; CIRCULATION; CYTOMETRY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EPITHELIUM CELL; FLOW CYTOMETRY; GENOME ANALYSIS; GENOMICS; GLYCOSYLATION; HUMAN; IMAGE ANALYSIS; IN SITU HYBRIDIZATION; KIDNEY; KIDNEY CARCINOMA; LABORATORY; MOLECULAR BIOLOGY; NIDATION; PREDICTION; PROGNOSIS; PROTEOMICS; REGULATORY MECHANISM; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TECHNIQUE; TUMOR CELL; TUMOR VOLUME;

EID: 11344256534     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. SILVER D.A., MORASH C., BRENNER P, CAMPELL S., RUSSO P. : Pathologic findings at the time of nephrectomy for renal mass. Ann Surg Oncol., 1997, 7, 570-574.
2. PARAF F., CHAUVEAU D., CHRETIEN Y., RICHARD S., GRUNFELD J.P., DROZ D. : Renal lesions in von Hippel-Lindau disease : immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins. Histopathology, 2000, 36, 457-65.
3. CAO Y., KARSTEN U., ZERBAN H., BANNASCH P. : Expression of MUC1, Thomsen-Friedenreich-related antigens, and cytokeratin 19 in human renal cell carcinomas and tubular clear cell lesions. Virchows Arch., 2000, 436, 119-126.
4. GIROLDI L.A., SHIMAZUI T., SCHALKEN J.A., YAMASAKI H., BRINGUIER P.P .: Classical cadherins in urological cancers. Morphologie, 2000, 84, 31-38.
5. FISCHER C., GEORG C., KRAUS S., TERPE H.J., LUEDECKE G., WEIDNER W. : CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res., 1999, 19, 1513-1517.
6. KIM Y.S., KANG Y.K., KIM J.B., HAN S.A., KIM K.I., PAIK S.R.: Beta-catenin expression and mutational analysis in renal cell carcinomas. Pathol. Int., 2000, 50, 725-730.
7. PAUL R., EWING C.M., ROBINSON J.C., MARSHALE F.F., JOHNSON K.R., WHEELOCK M.J., ISAACS W.B. : Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma. Cancer Res., 1997, 57, 2741-2748.
8. SHIMAZUI T., OOSTERWIJK E., AKAZA H., BRINGUIER P., RUIJTER E., VAN BERKEL H., WAKKA J.O., VAN BOKHOVEN A., DEBRUYNE F.M., SCHALKEN J.A. : Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma. Clin. Cancer Res., 1998, 4, 2419-2424.
9. KURODA N., NARUSE K., MIYAZAKI E., HAYASHI Y., YOSHIKAWA C., ASHIDA S., MORIKI T., YAMASAKI Y., NUMOTO S., YAMAMOTO Y., YAMASAKI I., HIROI M., SHUIN T., ENZAN H. : Vinculin : its possible use as a marker of normal collecting ducts and renal neoplasms with collecting duct system phenotype. Mod. Pathol., 2000, 13, 1109-1114.
10. LI G., PASSEBOSC-FAURE K., LAMBERT C., GENTIL-PERRET A., GENIN C., TOSTAIN J. : Cadherin-6 gene expression in conventional renal cell carcinomas : implication for defection of circulating renal cancer cells. Eur. Urol., 2002, 1 : 139.
11. GENG Y., BIFFI A., ENGELSTEIN D., RONCH E., FAUSTINI M., LAI H.K., ALBINO A.P., DI FRONZO G., NANUS D.M. : Expression of the kidney-associated differentiation glycoprotein gp160 and resistance to the antitumor effects of interferon alpha in renal cell carcinomas. Anticancer Res., 1998, 18, 1-7.
12. NANUS D.M., PFEFFER L.M., BANDER N.H., BAHRI S., ALBINO A.P. : Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res., 1990, 50, 4190-4194.
13. STANGE T., KETTMANN U., HOLZHAUSEN H.J., RIEMANN D. : Expression patterns of the ectopeptidases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 : immunoultrastructural topographic localization on different types of cultured cells. Acta Histochem., 1998, 100, 157-169.
14. CHU P., ARBER D.A. : Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am. J. Clin. Pathol., 2000, 113, 374-382.
15. AVERY A.K., BECKSTEAD J., RENSHAW A.A., CORLESS C.L. : Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am. J. Surg. Pathol., 2000, 24, 203-210.
16. KEHLEN A., GOHRING B., LANGNER J., RIEMANN D. : Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators. Clin. Exp. Immunol., 1998, 111, 435-441.
17. YOSHIDA S.O., IMAM A. : Monoclonal antibody to a proximal nephrogenic renal antigen : immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res., 1989, 49, 1802-1809.
18. AYHAN A., USUBUTUN A., OZEN H., YASUI W., TAHARA E. : nm23 protein expression in renal cell tumors : the role of the cell type. Oncol Rep., 1998, 5, 979-983.
19. LU J.J., KAKEHI Y., TAKAHASHI T., WU X.X., YUASA T., YOSHIKI T., OKADA Y., TERACHI T., OGAWA O. : Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin. Cancer Res., 2000, 6, 3166-3171.
20. TAKENAWA J., KANEKO Y., KISHISHITA M., HIGASHITSUJI H., NISHIYAMA H., TERACHI T., ARAI Y., YOSHIDA O., FUKUMOTO M., FUJITA J. : Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. Int. J. Cancer, 1998, 79, 1-7.
21. D'ANDREA V., MALINOVSKY L., BERNI A., BIANCARI F., BIASSONI L., DI MATTEO F.M., CORBELLINI L., FALVO L., SANTONI F., SPYROU M., DE ANTONI E. : The immunolocalization of PGP 9.5 in normal human kidney and renal cell carcinoma. G Chir., 1997, 18, 521-524.
22. WALDHERR R., SCHWECHHEIMER K. : Co-expression of cytokeratin and vimentin intermediate-sized filaments in renal cell carcinomas. Comparative study of the intermediate-sized filament distribution in renal cell carcinomas and normal human kidney. Virchows Arch. A. Pathol. Anat. Histopathol., 1985, 408, 15-27.
23. HAN A.C., DUSZAK R. JR. : Coexpression of cytokeratins 7 and 20 confirms urothelial carcinoma presenting as an intrarenal tumor. Cancer, 1999, 86, 2327-2330.
24. CHU P.G., WEISS L.M. : Cytokeratin 14 immunoreactivity distinguishes oncocytic tumour from its renal mimics : an immunohistochemical study of 63 cases. Histopathology, 2001, 39, 455-462.
25. SHIMAZUI T., OOSTERWIJK-WAKKA J., AKAZA H., BRINGUIER P.P., RUIJTER E., DEBRUYNE F.M., SCHALKEN J.A., OOSTERWIJK E. : Alterations in expression of cadherin-6 and E-cadherin during kidney development and in renal cell carcinoma. Eur. Urol., 2000, 38, 331-338.
26. CHO E.A., PATTERSON L.T., BROOKHISER W.T., MAH S., KINTNER C., DRESSLER G.R. : Differential expression and function of cadherin-6 during renal epithelium development. Development. 1998, 125, 803-812.
27. ARAI T., KAWACHI Y., ISHI K., KOYATSU J., KINA K. : Immunocylochemical diagnosis of Bellini duct carcinoma. Acta Cytol., 1997, 41, 1241-1242.
28. YOUNG A.N., AMIN M.B., MORENO C.S., LIM S.D., COHEN C., PETROS J.A., MARSHALL F.F., NEISH A.S. : Expression profiling of renal epithelial neoplasms. A method for tumor classification and discovery of diagnostic molecular markers. Am. J. Pathol., 2001, 158, 1639-1651.
29. MOCH H., SCHRAML P., BUBENDORF L., MIRLACHER M., KONOMEN J., GASSER T., MINTASCH M.J., KALLONIEMI O.P., SAUTER G. : High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol., 1999, 154, 981-986.
30. SCHAUB T.P., KARTENBECK J., KONIG J., SPRING H., DORSAM J., STAEHLER G., STORKEL S., THON W.F., KEPPLER D. : Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol., 1999, 10, 1159-1169.
31. WECHSEL H.W., PETRI E., BICHLER K.H., FEIL G. : Marker for renal cell carcinoma (RCC) : the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res., 1999, 19, 2583-2590.
32. OREMEK G.M., TEIGELKAMP S., KRAMER W., EIGENBRODT E., USADEL K.H. : The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res., 1999, 19, 2599-2601.
33. LIAO S.Y., AURELIO O.N., JAN-K., ZAVADA J., STANBRIDGE E.J. : Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res., 1997, 57, 2827-2831.
34. UEMURA H., NAKAGAWA Y., YOSHIDA K., SAGA S., YOSHIKAWA K., HIRAO Y., OOSTERWIJK E. : MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer, 1999, 81, 741-746.
35. MURAKAMI Y., KANDA K., TSUJI M., KANAYAMA H., KAGAWA S. : MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int., 1999, 83, 743-747.
36. IVANOV S., LIAO S.Y., IVANOVA A., DANILKOVITCH-MIAGKOVA A., TARASOVA N., WEIRICH G., MERRILL M.J., PROESCHOLDT M.A., OLDFIELD E.H., LEE J., ZAVADA J., WAHEED A., SLY W., LERMAN M.I., STANBRIDGE EJ. : Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol., 2001, 158, 905-919.
37. TURECI O., SAHIN U., VOLLMAR E., SIEMER S., GOTTERT E., SEITZ G., PARKKILA A.K., SHAH G.N., GRUBB J.H., PFREUNDSCHUH M., SLY W.S. : Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc. Natl. Acad. Sci. USA., 1998, 95, 7608-7613.
38. WYKOFF C.C., BEASLEY N., WATSON P.H., CAMPO L., CHIA S.K., ENGLISH R., PASTOREK J., SLY W.S., RATCLIFFE P., HARRIS A.L. : Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol., 2001, 158, 1011-1019.
39. OLIVE P.L., AQUINO-PARSONS C., MACPHAIL S.H., LIAO S.Y., RALEIGH J.A., LERMAN M.I., STANBRIDGE E.J. : Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res., 2001, 61, 8924-8929.
40. KOUKOURAKIS M.I., GIATROMANOLAKI A., SIVRIDIS E., SIMOPOULOS K., PASTOREK J., WYKOFF C.C., GATTER K.C., HARRIS A.L. : Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer Res., 2001, 7, 3399-3403.
41. GIATROMANOLAKI A., KOUKOURAKIS M.I., SIVRIDIS E., PASTOREK J., WYKOFF C.C., GATTER K.C., HARRIS A.L. : Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res., 2001, 61, 7992-7998.
42. TAKENAWA J., KANEKO Y., KISHISHITA M., HIGASHITSUJI H., NISHIYAMA H., TERACHI T, ARAI Y., YOSHIDA O., FUKUMOTO M., FUJITA J. : Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. Int. J. Cancer, 1998, 79, 1-7.
43. OOSTERWIJK E., BANDER N.H., DIVGI C.R., WELT S., WAKKA J.C., FINN R.D., CARSWELL E.A., LARSON S.M., WARNAAR S.O., FLEUREN G.J. : Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol., 1993, 11, 738-750.
44. LI G., PASSEBOSC-FAURE K., LAMBERT C., GENTIL-PERRET A., BLANC F., OOSTERWIJK E., MOSNIER J.F., GENIN C., TOSTAIN J. : The expression of G250/mm/CA9 antigen by flow cytometry : its possible implication for detection of micrometastatic renal cancer cells. Clin. Cancer Res., 2001, 7, 89-92.
45. LI G., PASSEBOSC-FAURE K., LAMBERT C., GENTIL-PERRET A., BLANC F., OOSTERWIJK E., MOSNIER J.F., GENIN C., TOSTAIN J. : Flow cytometric analysis of antigen expression in malignant and normal renal cells. Anticancer Res., 2000, 20, 2773-2778.
46. DE LA TAILLE A., KATZ A., CAO Y., MCKIERNAN J., BUTTYAN R., BURCHARDT M., BURCHARDT T., HAYEK O., OLSSON C.A., CHOPIN D.K., SAWCZUK I.S. : Blood-based RT-PCR assays of MN/CA9 or PSMA : clinical application in renal cancer patients. Urology, 2000, 56, 393-398.
47. MCKIERNAN J.M., BUTTYAN R., BANDER N.H., DE LA TAILLE A., STIFELMAN M.D., EMANUEL E.R., BAGIELLA E., RUBIN M.A., KATZ A.E., OLSSON C.A., SAWCZUK I.S. : The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer, 1999, 86, 492-497.
48. SATO K., KAWASHIMA S. : Calpain function in the modulation of signal transduction molecules. Biol Chem., 2001, 382, 743-751.
49. SANTAROSA M., FAVARO D., QUAIA M., GALLIGIONI E. : Expression of heat shock protein 72 in renal cell carcinoma : possible role and prognostic implications in cancer patients. Eur. J. Cancer, 1997, 33, 873-877.
50. GEISLER E., ANDAZ S., NIRMUL D., GHEEWALA P., SEHONANDA A., GERST P.H. : False-positive prostatic-specific antigen in the serum of a man with renal cell carcinoma. Br. J. Urol., 1997, 79, 299-300.
51. DE LA TAILLE A., CAO Y., SAWCZUK I.S., NOZEMU T., D'AGATI V., MCKIERNAN J.M., BAGIELLA E., BUTTYAN R., BURCHARDT M., OLSSON C.A., BANDER N., KATZ A.E. : Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients : a potential biomarker of vascular invasion. Cancer Detect Prev., 2000, 24, 579-588.
52. DUMAS P., GALA J.L., BERTEAU P., BRASSEUR F., ESCHWEGE P., PARADIS V., LACOUR B., PHILIPPE M., LORIC S. : Molecular expression of PSMA mRNA and protein in primary renal tumors. Int. J. Cancer, 1999, 80, 799-803.
53. RAE F., BULMER B., NICOL D., CLEMENTS J. : The human tissue kallikreins (KLKs 1-3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library. Immunopharmacology, 1999, 45, 83-88.
54. CLEMENTS J., WARD G., KAUSHAL A., HI S.I., KENNETT C., NICOL D. : A prostate-specific antigen-like protein associated with renal cell carcinoma in women. Clin. Cancer Res., 1997, 3, 1427-1431.
55. PUMMER K., WIRNSBERGER G., PURSTNER P., STETTNER H., WANDSCHNEIDER G. : False positive prostate specific antigen values in the sera of women with renal cell carcinoma. J Urol., 1992, 148, 21-23.
56. MCGREGOR D.K., KHURANA K.K., CAO C., TSAO C.C., AYALA G., KRISHNAN B., RO J.Y., LECHAGO J., TRUONG L.D. : Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'Renal Cell Carcinoma Marker'. Am. J. Surg. Pathol., 2001, 25, 1485-1492.
57. LEROY X., MOUKASSA D., COPIN M.C., SAINT F., MAZEMAN E., GOSSELIN B. : Utility of cytokeratin 7 for distinguishing chromophobe renal cell carcinoma from renal oncocytoma. Eur. Urol., 2000, 37, 484-487.
58. MAI K.T., BURNS B.F. : Chromophobe cell carcinoma and renal cell neoplasms with mucin-like changes. Acta Histochem., 2000, 102, 103-113.
59. SATOH M., HANDA K., SAITO S., TOKUYAMA S., ITO A., MIYAO N., ORIKASA S., HAKOMORI S. : Disialosyl galactosylgloboside as an adhesion molecule expressed on renal cell carcinoma and its relationship to metastatic potential. Cancer Res., 1996, 56, 1932-1938.
60. BASU M., HAWES J.W., LI Z., GHOSH S., KHAN F.A., ZHANG B.J., BASU S. : Biosynthesis in vitro of SA-Lex and SA-diLex by alppha 1-3 fucosyltransferases from colon carcinoma cells and embryonic brain tissues. Glycobiology, 1991, 5, 527-535.
61. MATSUSHITA Y., CLEARY K.R., OTA D.M., HOFF S.D., IRIMURA R. : Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases. Lab. Invest., 1990, 63, 780-791.
62. ITZKOWITZ S.H., SHI Z.R., KIM Y.S. : Heterogeneous expression of two oncodevelopmental antigens CEA and SSEA-1, in colorectal cancer. Histochem. J., 1986, 18, 155-163.
63. FRANCOIS C., VAN VELTHOVEN R., DE LATHOUWER O., MORENO C., PELTIER A., KALTNER H., SALMON I., GABIUS H.J., DANGUY A., DECAESTECKER C., KISS R. : Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am. J. Clin.Pathol., 1999, 112, 194-203.
64. FUJITA K., DENDA K., YAMAMOTO M., FUJIME M., IRIMURA T. : Expression of MUC1 inversely correlated with post-surgical survival of renal cell carcinoma patients. Br. J. Cancer. 1999, 80, 301-308.
65. KRAUS S., ABEL P.D., NACHTMANN C., LINSENMANN H.J., WEIDNER W., STAMP G.W., CHAUDHARY K.S., MITCHELL S.E., FRANKE P.E., LALANIEL N. : MUC1 mucin and trefoil 1 protein expression in renal cell carcinoma : correlation with prognosis. Hum. Pathol., 2002, 33, 60-67.
66. LEROY X., COPIN M.C., DEVISME L., BUISINE M.P., AUBERT J.P., GOSSELIN B., PORCHET N. : Expression of human mucin genes in normal kidney and renal cell carcinoma. Histopathology, 2002, 40, 450-457.
67. ELLIS I.O., HITCHCOCK A. : Tumor marker immunoreactivity in adenocarcinoma J. Clin. Pathol., 1988, 41, 1064-1067.
68. SELIGER B., RONGCUN Y., ATKINS D., HAMMERS S., HUBER C., STORKEL S., KIESSLING R. : HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int. J. Cancer, 2000, 87, 349-359.
69. LIPPONEN P., ESKELINEN M., SYRJANEN K. : Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br. J. Cancer, 1995, 71, 863-867.
70. NEUMANN E., ENGELSBERG A., DECKER J., STÖRKEL S., JAEGER E., HUBER C., SELIGER B. : Heterogeneous expression of Tumor associated antigen RAGE-1, PRAME, and Gluycoprotein 75 in human Renal Cell Carcinoma : Candidates for T cell based immunotherapies. Cancer Res., 1998, 58, 4090-4095.
71. SARTO C., MAROCCHI A., SANCHEZ J.C., GIANNONE D., FRUTIGER S., GOLAZ O., WILKINS M.R., DORO G., CAPPELLANO P., HUGHES G., HOCHSTRASSER D.F., MOCARELLI P. : Renal cell carcinoma and normal kidney protein expression. Electrophoresis, 1997, 18, 599-604.
72. VON EGGELING F., JUNKER K., FIEDLE W., WOLLSCHEID V., DURST M., CLAUSSEN U., ERNST G. : Mass spectrometry meets chip technology : a new proteomic tool in cancer research ? Electrophoresis. 2001, 22, 2898-2902.
73. FEARON E.R. : Genetic alteration underlying colorectal tumorigenesis. Cancer Surveys, 1992, 12, 119-136.
74. SINIK Z., ALKIBAY T., ATAOGLU O., BIRI H., SOZEN S., DENIZ N., KARAOGLAN U., BOZKIRLI I. : Nuclear p53 overexpression in bladder, prostate, and renal carcinomas. Int. J. Urol., 1997, 4, 546-551.
75. LAI R., EL DABBAGH L., MOURAD W.A. : Mutant p53 expression in kidney tubules adjacent to renal cell carcinoma: evidence of a precursor lesion. Mod. Pathol., 1996, 9, 690-695.
76. MOCH H., SAUTER G., GASSER T.C., BUCHHOLZ N., BUBENDORF L., RICHTER J., JIANG F., DELLAS A., MIHATSCH M.J. : p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol. Res., 1997, 25, 25-30.
77. SHIINA H., IGAWA M., URAKAMI S., SHIRAKAWA H., ISHIBE T., KAWANISHI M. : Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma. Eur. Urol., 1997, 31, 73-80.
78. HAITEL A., WIENER H.G., BLASCHITZ U., MARBERGER M., SUSANI M. : Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type : an immunohistochemical study correlating grading, staging, and proliferation markers. Cancer, 1999, 85, 1593-1598.
79. SEJIMA T., MIYAGAWA I. : Expression of bcl-2, p53 oncoprotein and proliferating cell nuclear antigen in renal cell carcinoma. Eur. Urol., 1999, 35, 242-248.
80. WALSH C.J., KAY E.W., LYNCH T., WALSH M., MILBURN C., MCLEAN P.A., MURPHY D., DONOVAN M., LEADER M.B. : Evaluation of p53 protein expression in renal cell carcinoma : comparison of two antibodies. Br. J. Biomed. Sci., 1996, 53, 179-181.
81. KUCZYK M.A., SERTH J., BOKEMEYER C., JONASSEN J., ARNDT H., PAESLACK U., WERNER M., TAN H.K., JONAS U.: Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens. Int. J. Cancer, 1995, 64, 399-406.
82. DANIEL L., LECHEVALLIER E., GIORGI R., SICHEZ H., ZATTARA-CANNONI H., FIGARELLA-BRANGER D., COULANGE C. : Pax-2 expression in adult renal tumors. Hum. Pathol., 2001, 32, 282-287.
83. ENGERS R., ZWAKA T.P., GOHR L., WEBER A., GERHARZ C.D., GABBERT H.E. : Tiam1 mutations in human renal-cell carcinomas. Int. J. Cancer, 2000, 88, 369-376.
84. AALTOMAA S., LIPPONEN P., ALA-OPAS M., ESKELINEN M., SYRJANEN K., KOSMA V.M. : Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br. J. Cancer, 1999, 80, 2001-2007.
85. BOSARI S., VIALE G., BOSSI P., MAGGIONI M., COGGI G., MURRAY J.J., LEE A.K : Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J. Natl. Cancer Inst., 1994, 86, 681-687.
86. MARXSEN J., SCHMIEGEL W., RODER C., HARDER R., JUHL H., HENNE-BRUNS D., KREMER B., KALTHOFF H. : Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br. J. Cancer, 1994, 70, 1031-1034.
87. SHIBATA Y., KOTANAGI H., ANDOH H., KOYAMA K., ITOH H., KUDO S. : Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Dis. Colon Rectum., 1996, 39, 1269-1274.
88. LAVIEILLE J.P., LUBIN R., SOUSSI T., REYT E., BRAMBILLA C., RIVA C. : Analysis of p53 antibody response in patients with squamous celle carcinoma of the head and neck. Anticancer Res., 1996, 16, 2385-238.
89. IQBAL M.A., AKHTAR M., ULMER C., AL-DAYEL F., PATERSON M.C. : FISH analysis in chromophobe renal-cell carcinoma. Diagn Cytopathol., 2000, 22, 3-6.
90. YAMAKAWA K., TAKAHASHI E., MURATA M., OKUI K., YOKOYAMA S., NAKAMURA Y. : Detailed mapping aroud the breakpoint of (3;8) translocation in familial renal cell carcinoma and FRA3B. Genomics 1992, 14, 412-416.
91. PODOLSKI J., BYRSKI T., ZAJACZEK S., DRUCK T., ZIMONJIC D.B., POPESCU N.C., KATA G., BOROWKA A., GRONWALD J., LUBINSKI J., HUEBNER K. : Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. J Hum Genet., 2001, 46, 685-93.
92. DRUCK T., PODOLSKI J., BYRSKI T., WYRWICZ L., ZAJACZEK S., KATA G., BOROWKA A., LUBINSKI J., HUEBNER K. : The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. J. Hum. Genet., 2001, 46, 583-589.
93. ELEVELD M.J., BODMER D., MERKX G., SIEPMAN A., SPRENGER S.H., WETERMAN M.A., LIGTENBERG M.J., KAMP J., STAPPER W., JEUKEN J.W., SMEETS D., SMITS A., GEURTS VAN KESSEL A. : Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). Genes Chromosomes Cancer, 2001, 31, 23-32.
94. ZATTARA-CANNONI H., DANIEL L., ROLL P., COULANGE C., VAGNER-CAPODANO A. : Molecular cytogenetics of t(X;1)(p11.2;q21) with complex rearrangements in a renal cell carcinoma. Cancer Genet. Cytogenet., 2000, 123, 61-64.
95. BECK J.L., HOPMAN A.H., FEITZ W.F., SCHALKEN J., SCHAAFSMA H.E., VAN DE KAA C.A., RAMAEKERS F.C., HANSELAARR A.G., DE WILDE P.C. : Numerical aberrations of chromosomes 1 and 7 in renal cell carcinomas as detected by interphase cytogenetics. J. Pathol., 1995, 176, 123-135.
96. PAPADOPOULOS I., WEICHERT-JACOBSEN K., WACKER H.H., SPRENGER E. : Correlation between DNA ploidy, proliferation marker Ki-67 and early tumor progression in renal cell carcinoma. A prospective study. Eur. Urol., 1997, 31, 49-53.
97. SCHAFHAUSER W, LIEDL T, ELSASSER D, ZORCHER T, SCHROTT KM. : Flow cytometric analysis of DNA-aneuploidy subgroups and proliferation in renal cell carcinoma. Anticancer Res., 1999, 19, 1471-1475.
98. LI G., COTTIER M., SABIDO O., GENTIL-PERRET A., LAMBERT C., PASSEBOSC-FAURE K., GENIN C., TOSTAIN J. : The in vivo DNA aneuploidization during expansion of conventional Renal Cell. Carcinoma. In vivo, 2002 ; 16, 341-344.
99. ABOU-REBYEH H., BORGMANN V., NAGEL R., AL-ABADI H. : DNA ploidy is a valuable predictor for prognosis of patients with resected renal cell carcinoma. Cancer, 2001, 92, 2280-2285.
100. SILVERIO F.D., CASALE P., COLELLA D., ANDREA L., SECCARECCIA F., SCIARRA A. : Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer, 2000, 88, 835-843.
101. RENSHAW A.A., LOUGHLIN K.R., DUTTA A. : Cyclin A and MIB1 (Ki67) as markers of proliferative activity in primary renal neoplasms. Mod. Pathol., 1998, 11, 963-966.
102. TERZOLO M., BOCCUZZI A., BOVIO S., CAPPIA S., DE GIULI P., ALI A., PACCOTTI P., PORPIGLIA F., FONTANA D., ANGELI A. : Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology, 2001, 57, 176-82.
103. LINDEN M.D.; EL-NAGGAR A.K., NATHANSON S.D., JACOBSON G., ZARBO R.J. : Lack of correlation between flow cytometric and immunohistologic proliferation measurements of tumors. Mod. Pathol., 1996, 9, 682-689.
104. RENSHAW A.A., LOUGHLIN K.R., DUTTA A. : Cyclin A and MIB1 (Ki67) as markers of proliferative activity in primary renal neoplasms. Mod. Pathol, 1998, 11, 963-966.
105. MORELL-QUADRENY L., CLAR-BLANCH F., FENOLLOSA-ENTERNA B., PEREZ-BACETE M., MARTINEZ-LORENTE A., LLOMBART-BOSCH A. : Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma. Anticancer Res., 1998, 18, 677-82.
106. YOKOGI H. : Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in patients with renal cell carcinoma. Cancer, 1996, 78, 819-826.
107. PICH A., VALENTE G., AZZONI L., STRAMIGNONI A., MARGARIA E., TASSO M. : Argyrophilic nucleolar organizer region counts and Ki-67 scores in human renal cell carcinoma. Pathol. Res. Pract., 1991, 187, 482-486.
108. VAN DIEST P.J., BRUGAL G., BAAK J.P. : Proliferation markers in tumours : interpretation and clinical value. J. Clin. Pathol., 1998, 51, 716-724.
109. RENDON R.A., STANIETZKY N., PANZARELLA T., ROBINETTE M., KLOTZ L.H., THURSTON W., JEWETT M.A. : The natural history of small renal masses. J Urol., 2000, 164, 1143-1147.
110. GRIFFITH T.S., FIALKOV J.M., SCOTT D.L., AZUHATA T., WILLIAMS R.D., WALL N.R., ALTIERI D.C., SANDLER A.D. : Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res., 2002, 62, 3093-3099.
111. KIM Y.S., KIM K.H., CHOI J.A., LEE J.H., KIM H.K., WON N.H., KIM I. : Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas : correlation with the prognostic factors. Arch. Pathol. Lab. Med., 2000, 124, 687-693.
112. NONOMURA N., NISHIMURA K., ONO Y., FUKUI T., HARADA Y., TAKAHA N., TAKAHARA S., OKUYAMA A. : Soluble Fas in serum from patients with renal cell carcinoma. Urology, 2000, 55, 151-155.
113. MIYAKE H., HARA S., ZELLWEGER T., KAMIDONO S., GLEAVE M.E., HARA I. : Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol. Urol., 2001, 5, 105-111.
114. GERHARZ C.D., RAMP U., DEJOSEZ M., MAHOTKA C., CZARNOTTA B., BRETSCHNEIDER U., LORENZ I., MULLER M., KRAMMER P.H., GABBERT H.E. : Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas : an important factor for evasion from negative growth control. Lab. Invest. 1999, 79, 1521-1534.
115. OLIVE C., CHEUNG C., NICOL D., FALK M.C. : Expression of apoptotic regulatory molecules in renal cell carcinoma: elevated expression of Fas ligand. Immunol Cell Biol., 1999, 77, 11-18.
116. NISHIMATSU H., TAKEUCHI T., UEKI T., KAJIWARA T., MORIYAMA N., ISHIDA T., LI B., KAKIZOE T., KITAMURA T. : CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo. Cancer Immunol. Immunother., 1999, 48, 56-61.
117. SASANO H., YAMAKI H., NAGURA H. : Detection of apoptotic cells in cytology specimens: an application of TdT-mediated dUTP-biotin nick end labeling to cell smears. Diagn. Cytopathol. 1998, 18, 398-402.
118. ROMAN S., PETRUSCA D., MOLDOVAN I., PARAOAN M., PETRESCU A., DAMIAN D., NOICA N., SULICA A. : Evaluation of apoptosis of tumor and of apparently normal cells in human renal carcinoma. Immunol. Lett., 1999, 67, 15-22.
119. LAGER D.J., SLAGEL D.D., PALECHEK P.L. : The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod. Pathol., 1994, 7, 544-548.
120. YOSHIDA K., TOSAKA A., TAKEUCHI S., KOBAYASHI N. : Epidermal growth factor receptor content in renal cell carcinoma.Cancer, 1994, 73, 1913-1918.
121. JOHN A., TUSZYNSKI G. : The role of matrix 112 in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res., 2001, 7, 14-23.
122. WANG Y. : The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med. Res. Rev., 2001, 21, 146-170.
123. DUFFY M.J., MAGUIRE T.M., MCDERMOTT E.W., O'HIGGINS N. : Urokinase plasminogen activator : a prognostic marker in multiple types of cancer. J. Surg. Oncol., 1999, 71, 130-135.
124. FOEKENS J.A., PETERS H.A., LOOK M.P., PORTENGEN H., SCHMITT M., KRAMER M.D., BRÜNNER N., JÄNICKE F., MEIJER-VAN GELDER M.E., HENZEN-LOGMANS S.C., VAN PUTTEN W.L.J., KLIJN J.G.M. : The Urokinase system of Plasminogen activation and prognosis in 2780 Breast cancer patients. Cancer Res., 2000, 60, 636-643.
125. KIRCHHEIMER J.C., PFLUGER H., HIENERT G., BINDER B.R.: Increased urokinase activity to antigen ratio in human renal-cell carcinoma. Int. J. Cancer, 1985, 35, 737-741.
126. HOFMANN R., LEHMER A., BURESCH M., HARTUNG R., ULM K. : Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer, 1996, 78, 487-492.
127. HEMMERLEIN B., SCHERBENING J., KUGLER A., RADZUN H.J. : Expression of VCAM-1, ICAM-1, E- and P-selectin and tumour-associated macrophages in renal cell carcinoma. Histopathology, 2000, 37, 78-83.
128. DROZ D., PATEY N., PARAF F., CHRETIEN Y., GOGUSEV J. : Composition of extracellular matrix and distribution of cell adhesion molecules in renal cell tumors. Lab. Invest., 1994, 71, 710-718.
129. KOGA H., NAITO S., NAKASHIMA M., HASEGAWA S., WATANABE T., KUMAZAWA J. : A flow cytometric analysis of the expression of adhesion molecules on human renal cell carcinoma cells with different metastatic potentials. Eur. Urol., 1997, 31, 86-91.
130. WYCKOFF J.B., JONES J.G., CONDEELIS J.S., SEGALL J.E. : A critical step in metastasis : in vivo analysis of intravasation at the primary tumor. Cancer Res., 2000, 60, 2504-2511.
131. DANIEL L., LECHEVALLIER E., GIORGI R., LINDNER V., DE FROMONT M., VIEILLEFOND A., COULANGE C., FIGARELLA-BRANGER D. : CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinomas. J. Pathol., 2001, 193, 345-349.
132. GILCREASE M.Z., TRUONG L., BROWN R.W. : Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Hum. Pathol., 1996, 27, 1355-1360.
133. FISCHER C., GEORG C., KRAUS S., TERPE H.J., LUEDECKE G., WEIDNER W. : CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res., 1999, 19, 1513-1517.
134. BENNETT K.L., MODRELL B., GREENFIELD B., BARTOLAZZI A., STAMENKOVIC I., PEACH R., JACKSON D.G., SPRING F., ARUFFO A. : Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J. Cell Biol., 1995, 131, 1623-1633.
135. PARADIS V., FERLICOT S., GHANNAM E., ZEIMOURA L., BLANCHET P., ESCHWEGE P., JARDIN A., BENOIT G., BEDOSSA P. : CD44 is an independent prognostic factor in conventional renal cell carcinomas. J. Urol., 1999, 161, 1984-1987.
136. MASUDA M., TAKANO Y., IKI M., MAKIYAMA K., NOGUCHI S., HOSAKA M. : Expression and prognostic value of CD44 isoforms in transitional cell carcinoma of renal pelvis and ureter. J. Urol., 1999, 161, 805-808.
137. HARA I., MIYAKE H., YAMANAKA K., HARA S., ARAKAWA S., KAMIDONO S. : Expression of CD44 adhesion molecules in nonpapillary renal cell carcinoma and normal kidneys. Urology, 1999, 54, 562-566.
138. LEIN M., JUNG K., WEISS S., SCHNORR D., LOENING S.A. : Soluble CD44 variants in the serum of patients with urological malignancies. Oncology, 1997, 54, 226-230.
139. SIMPSON S.J., VACHULA M., KENNEDY M.J., KAIZER H., COON J.S., GHALIE R., WILLIAMS S., VAN EPPS D. : Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp. Hematol., 1995, 23, 1062-1068.
140. -7. Proc. Natl. Acad. Sci USA., 1995, 92, 537-541.
141. BILKENROTH U., TAUBERT H., RIEMANN D., REBMANN U., HEYNEMANN H., MEYE A. : Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. Int. J. Cancer, 2001, 92, 577-582.
142. LI G., PASSEBOSC-FAURE K., LAMBERT C., GENTIL-PERRET A., MOSNIER J.F., GENIN C., TOSTAIN J. : Mise au point d'une méthode de détection rapide et sensible des ARNm MN/CA9 et cadhérine-6 pour le diagnostic moléculaire de l'adénocarcinome rénal à cellules conventionnelles. Prog. Urol., 2002, 12, 55A.
143. HAUTKAPPE A.L.A., LU M., MUELLER H., BEX A., HARSTRICK A., ROGGENDORF M., RUEBBEN H. : Detection of germ-cell tumor cells in the peripheral blood by nested reverse transcription polymerase chain reaction for alpha-fetoprotein messenger RNA and beta Human chorionic gonadotrophin messenger RNA. Cancer Res., 2000, 60, 3170-3174.
144. DE LA TAILLE A., SALOMON L., COLOMBEL M., ABBOU C.C., CHOPIN D., GROUX-MUSCATELLI B. : Detection of circulating prostatic cells with RT-PCR PSA in prostatic cancer. Prog. Urol., 1999, 9, 1084-1089.
145. MILLON R., JACQMIN D., MULLER D., GUILLOT J., EBER M., ABECASSIS J. : Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients : clinical implications. Eur. Urol., 1999, 36, 278-285.
146. GAO C.L., DEAN R.C., PINTO A., MOONEYHAN R., CONNELLY R.R., MCLEOD D.G., SRIVASTAVA S., MOUL J.W. : Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J. Urol., 1999, 161, 1070-1076.